Cogent Biosciences Q3 net loss $35.1M; cash $289.1M, runway into 2025; Phase 3 PEAK trial started

Cogent Biosciences, Inc.

2022-Q3 EPS reported -$1.84

Net loss $35.1M vs $19.1M YoY; R&D expense $29.9M (up from $14.8M) due to trials and team expansion.
Cash & securities $289.1M as of Sep 30, 2022; cash runway expected into 2025.
Phase 3 PEAK trial of bezuclastinib + sunitinib in second-line GIST patients initiated.
Optimized bezuclastinib formulation shows >40% exposure improvement; potential patent protection to 2043.
G&A expense $6.9M vs $5.0M YoY; non-cash stock comp included.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cogent Biosciences, Inc. reported the quarter ended September 30, 2022 results: net income $35.1 million.

Period: the quarter ended September 30, 2022
Net income: $35.1 million
Result: reported results

Exact text from the filing

Net Loss: Net loss was $35.1 million for the th

View on SEC.gov

Browse all earnings releases →

Cogent Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-024675

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.